About

Chugai Group’s mission is to create innovative drugs for the benefit of patients.

Company Profile

Chugai Pharmabody Research (CPR) was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd. (“Chugai”), Japan’ s No.1 biopharmaceutical company, in January 2012 and started operations on July 2, 2012. CPR is Chugai’s third satellite research institute, following others in Japan and Singapore.

CPR conducts research on the generation of new antibody drug clinical candidates focusing on high value First-in-Class and Best-in-Class antibodies for a variety of targets, and utilising Chugai’ s proprietary innovative antibody engineering technologies such as the Recycling Antibody® technology and the Sweeping Antibody® technology.

Company Name

Chugai Pharmabody Research Pte. Ltd.
(“Pharmabody” is coined from the words pharmaceutical and antibody.)

Establishment

January 10, 2012

Location

3 Biopolis Drive, #07–11 to 16 Synapse, Singapore 138623

Commencement of Operations

July 2, 2012

Capital

S$ 1.5 million

CEO

Tomoyuki Igawa Ph.D.

Shareholder

Wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd.

Board of Directors

Sir David Lane, Chairman of the Board
Tomoyuki Igawa, Director and CEO
Hisafumi Okabe, Director and COO
Arnold Levine, Director

Number of Employees

120 (as at 1st April 2020)

Message from the CEO

“”

TOMOYUKI IGAWA PH.D.

Director, Chief Executive Officer

In the global medical field, there are many diseases for which there are no drugs, or where current drugs are insufficient to address the medical needs of patients. Chugai Pharmabody Research (CPR) is a subsidiary company of Chugai Pharmaceutical in Japan, a member of Roche group, and is committed to address these unmet needs by specialising in the field of antibody drug discovery, utilising proprietary antibody engineering technologies. Creating innovative antibody drugs not only requires the identification of appropriate targets, but also superior technologies.

CPR’s mission is to continuously create innovative antibody drug clinical candidates by fully utilising proprietary antibody engineering technologies established by Chugai, such as recycling antibody, sweeping antibody, bispecific antibody, and other novel types of antibody, as well as to establish novel antibody engineering technologies to address unmet medical needs, and continuously achieve competitive advantages in highly intense antibody drug discovery competition. By taking full advantage of Singapore’s innovative environment for world-class biomedical research, cutting-edge infrastructure, highly trained and multi-national scientists and government support, we have established highly sophisticated antibody generation, engineering and evaluation systems, and we are now a global leader in the field of antibody drug discovery research.

CPR works as a unified team, and we are committed to making the best use of our R&D investments, resources and talents. Taken together, our aspirations are to discover innovative solutions for unmet medical needs, and to translate advanced science and technologies into revolutionary new antibody drugs that can significantly improve patients’ lives and contribute to the medical community around the world.

VISION

As a member of the Chugai Group, the goal of CPR is to develop innovative drugs to address unmet medical needs around the world. We rely on the scientific and technological strengths of our diverse team to innovate, advance and sustain patient-centric healthcare with a truly inclusive approach.

History

“”

1925

Juzo Ueno founded Chugai Shinkyaku Co., Ltd. and began the import and sale of medicinal drugs.

“”

1943

Reorganized into a corporation and company name changed to Chugai Pharmaceutical Co., Ltd. (Photo of Matsunage Plant)

“”

2002

Announcement of the strategic alliance with Roche and started business with Roche.

“”

2012

Established Chugai Pharmabody Research Pte. Ltd. In Singapore

“”

2018

Announcement of Business Expansion of Chugai Pharmabody Research Pte. Ltd.

Sir David Lane

Chairman of the Board and Chief Scientist at A*Star

With its proprietary antibody research technologies, CPR has great potential to create a world leading technology platform that transforms the efficacy of antibody based drugs and to contribute to a community of innovation. Since its establishment, through the research performance and other external activities such as organization of antibody symposium, I realize that CPR’s presence in Singapore and expectation from others have been increasing. I am very proud to help CPR generate a pipeline of innovative products that will help patients around the world and interact very well with Singapore international research community.

Our Team

“”

Admin Division

The Administration Division is responsible for the planning and execution of a wide range of administrative services which support the research activities of CPR.

More >
“”

Research Division

Our research units are crucial in the antibody discovery and development process, which they achieve with a high degree of independence.

More >
“” “”

At CPR, we value our people according to the pillars of ART: Acknowledgement, Recognition and Trust. By acknowledging our people’s contribution no matter how small it is, recognising their efforts, not just by management but by each other, and placing trust in our people to empower them, CPR helps to support our people’s growth as business professionals and as individuals.

Our People

At CPR, we value our people according to the pillars of ART: Acknowledgement, Recognition and Trust. By acknowledging our people’s contribution no matter how small it is, recognising their efforts, not just by management but by each other, and placing trust in our people to empower them, CPR helps to support our people’s growth as business professionals and as individuals.